P&T/Formulary Committee Actions (1Q18)
|
|
- Mary Woods
- 5 years ago
- Views:
Transcription
1 P&T/Formulary Committee s (1Q18) 1Q2018 Marketplace Standard (HIEx) Additions and/or Revisions effective: April 1, 2018 Deletions effective: April 1, 2018 for NEW member prescriptions; July 1, 2018 for EXISTING member prescriptions Elevate Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) P&T/Formulary Committee s 1Q 2018 (Effective April 1, 2018) Marketplace Standard Formulary Committee s HIV Biktarvy Drug ImmunomodulaƟng Biologics bictegravir/ emtricitabine/ tenofovir alafenamide N/A C=2 N/A A=QL CHANGE Biktarvy to Preferred Brand Tier (Tier 2). ADD QL on Biktarvy as follows: 1 tablet per day Actemra tocilizumab SC 4 S=4 PA CHANGE PA guideline on Actemra SC. Cimzia certolizumab 4 S=4 PA CHANGE PA guideline on Cimzia. Cosentyx secukinumab 4 S=4 PA CHANGE PA guideline on Cosentyx. Enbrel etanercept 4 S=4 PA CHANGE PA guideline on Enbrel. Humira adalimumab 4 S=4 PA CHANGE PA guideline on Humira. Kevzara sarilumab 4 S=4 PA CHANGE PA guideline on Kevzara Kineret anakinra 4 S=4 PA CHANGE PA guideline on Kineret. Orencia abatacept SC 4 S=4 PA CHANGE PA guideline on Orencia SC. Otezla apremilast 4 S=4 PA CHANGE PA guideline on Otezla. Siliq brodalumab 4 S=4 PA CHANGE PA guideline on Siliq. Simponi 50mg/0.5ml golimumab SC 50mg/0.5ml 4 S=4 PA CHANGE PA guideline on Simponi SC. Simponi 100mg/ml golimumab SC 100mg/ml 4 S=4 PA CHANGE PA guideline on Simponi SC. Stelara ustekinumab 4 S=4 PA CHANGE PA guideline on Stelara. Taltz ixekizumab 4 S=4 PA CHANGE PA guideline on Taltz. Tremfya guselkumab 4 S=4 PA CHANGE PA guideline on Trmfya. Xeljanz tofacitinib 4 S=4 PA CHANGE PA guideline on Xelijanz. Xeljanz XR tofacitinib extended release 4 S=4 PA CHANGE PA guideline on Xelijanz XR. ImmunomodulaƟng Biologics (NSA) Actemra tocilizumab IV 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Actemra IV. Entyvio vedolizumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Entyvio. Inflectra infliximab dyyb 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Inflectra. Orencia abatacept IV 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Orencia IV. Remicade infliximab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Remicade. Renflexis infliximab abda 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Renflexis. Rituxan rituximab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Rituxan.
2 Simponi Aria golimumab IV 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Simponi Aria. Hemophilia Hemlibra emicizumab 4 S=4 PA* CHANGE interim PA to final PA guideline on Hemlibra.
3 Drug Oncology Oral Calquence acalabrutinib 4 S=4 PA* CHANGE PA guideline on Calquence. Alunbrig brigatinib 4 S=4 PA CHANGE PA guideline on Alunbrig. Zelboraf vemurafenib 4 S=4 PA, QL Alecensa alectinib 4 S=4 PA, QL Sutent sunitinib 4 S=4 PA, QL MAINTAIN QL on Zelboraf. CHANGE PA guideline on Zelboraf. MAINTAIN QL on Alecensa. CHANGE PA guideline on Alecensa. MAINTAIN QL on Sutent. CHANGE PA guideline on Sutent. Cabometyx cabozantinib tablet 4 S=4 PA CHANGE PA guideline on Cabometyx. Bosulif bosutinib 4 S=4 PA, QL, QL Lynparza olaparib 4 S=4 PA, QL CHANGE PA guideline on Bosulif. CHANGE QL on Bosulif as follows: CHANGE PA guideline on Lynparza. MAINTAIN QL on Lynparza. Gilotrif afatinib 4 S=4 PA CHANGE PA guideline on Gilotif. Gleostine lomustine 4 S=4 none A=PA ADD PA guideline on Gleostine. Prevymis letermovir, oral 4 S=4 PA* CHANGE interim PA guideline on Prevymis to final PA Oncology Non Oral, NSA Faslodex fulvestrant 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Faslodex. Adcetris brentuximab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Adcentris. Gazyva obinutuzumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Gazyva Avastin bevacizumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Avastin Opdivo nivolumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Opdivo Perjeta pertuzumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Perjeta Xgeva denosumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Xgeva Prevymis letermovir, IV 4 S=4 PA^* ^ Orphan Diseases Mepsevii vestronidase alfa vjbk 4 S=4 PA^* ^ Luxturna voretigene neparvovec 4 S=4 PA^* ^ Infectious Disease CHANGE interim PA (NSA) guideline on Prevymis IV to final PA (NSA) guideline CHANGE interim PA (NSA) guideline on Mepsevii to final PA (NSA) CHANGE interim PA (NSA) guideline on Luxturna to final PA (NSA) ADD QL on Solosec as follows : 1 single dose oral packet per 30 days. Solosec secnidazole 3 S=3 none A=QL, ST ADD ST on Solosec as follows: Trial two of the following agents: oral metronidazole, oral tinidazole, oral clindamycin; metronidazole gel (0.75%), clindamycin cream (2%) in the previous 365 days. ADD QL on Cleocin: 3 intravaginal ovules (1 box) per 30 days Cleocin Clindamycin, intravaginal 3 S=3 none A=QL, ST ADD ST on Cleocin: Trial two of the following agents: oral metronidazole, oral tinidazole, oral clindamycin; metronidazole gel (0.75%), clindamycin cream (2%) in the previous 365 days. Ximino minocycline ER cap 3 S=3 none A=QL, ST, AGE ADD QL on Ximino as follows: 1 ER capsule daily. ADD ST on Ximino as follows: Trial of generic IR Minocycline tablets or generic IR Minocycline capsules in the previous 120 days. Allergy Odactra house dust mite allergen 3 C=2 PA* ADD AGE on Ximino as follows: 12 years of CHANGE Odactra to Preferred Brand (Tier 2) CHANGE interim PA guideline on Odactra to final PA Ragwitek ragweed pollen allergen 2 S=2 PA CHANGE PA guideline on Ragwitek. Grastek timothy grass pollen allergen 2 S=2 PA CHANGE PA guideline on Grastek.
4 Oralair Drug mixed grass pollen allergen 2 3= (100/300IR tablet) S=2 S=3 (100/300IR tablet) PA CHANGE PA guideline on Oralair. ADD QL on Xhance as follows: 32 ml (2 inhalation devices) per 30 days. Xhance fluticasone propionate 3 S=3 none A=QL, ST ADD ST on Xhance as follows: Trial of 2 of the following inhaled nasal corticosteriods: mometasone, fluticasone propionate/furoate, flunisolide, beclomethasone (Qnasl) in the previous 365 days. Non Oral NSAIDs Sprix ketorolac 3 S=3 QL A=ST MAINTAIN QL on Sprix. ADD ST on Spri as follows: Trial 1 generic NSAID in the previous 120 days. Indocin indomethacin suppositories 2 C=3 none A=PA GNRH agonists CHANGE Indocin to Non Preferred Brand Tier (Tier 3). ADD PA guideline on Indocin. Triptodur triptorelin 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Triptodur. Supprelin LA histrelin 4 S=4 none A=PA^ ADD PA (NSA) guideline on Supprelin LA. Lupon Depot Ped leuprolide 4 S=4 none A=PA^ ADD PA (NSA) guideline on Lupron Depot Ped Misc Drugs Oral Tracleer bosentan 4 S=4 PA CHANGE PA guideline on Tracleer. Adempas riociguat 4 S=4 PA CHANGE PA guideline on Adempas. Sensipar cinacalcet 3 S=3 none A=QL ADD QL on Sensipar as follows: 30 mg: 2 tablets per day 60 mg: 2 tablets per day 90 mg: 4 tablets per day ADD QL on Lyrica CR as follows: 82.5 mg, 165 mg: 3 tablets per day, 330 mg: 2 tablets per day Lyrica CR pregabalin 3 S=3 PA D=PA A=QL, ST ADD ST on Lyrica CR as follows: Trial of 2 of the following: gabapentin, tricyclic antidepressants (amitripyline, nortriptyline/notriptyline solution, desipramine, doxepin capsules/solution, imipramine, maprotilene), duloxetine, venlafaxine,valproic acid / divalproex in the previous 365 days. Flolipid simvastatin suspension 3 S=3 QL,ST Silenor doxepin 2 S=2 QL, ST Misc Drugs Non Oral D=QL,ST A=PA C=ST DELETE PA on Lyrica CR. DELETE QL and ST on Flolipid. ADD PA guideline on Flolipid. MAINTAIN QL on Silenor. CHANGE ST on Silenor as follows: a trial of one of the following: zolpidem IR, zaleplon, eszopiclone, doxepin 10 mg/ml solution, or doxepin 10 mg capsule in the previous 120 days. Parsabiv etelcalcetide 4 S=4 PA*^ ^ Fasenra benralizumab 4 S=4 PA*^ ^ CHANGE interim PA (NSA) guideline on Parsabiv to final PA (NSA) CHANGE interim PA (NSA) guideline on Fasenra to final PA (NSA) Nucala mepolizumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Nucala. Cinqair reslizumab 4 S=4 PA^ ^ CHANGE PA (NSA) guideline on Cinqair Durolane hyaluronic acid NC^ S=NC^ PA*^ ^ Impoyz clobetasol 0.025% cream 3 S=3 none A=ST Rx Cough Codeine and Hydrocodone Tuzistra XR codeine/ chlorpheniramine 3 S=3 AGE, QL, ST Codeine/ Phenylephrine/ Promethazine Codeine/ Phenylephrine/ Promethazine C=AGE S=ST, QL 1 S=1 AGE C=AGE Promethazine/ Codeine Promethazine/ Codeine 1 S=1 AGE C=AGE CHANGE interim PA (NSA) guideline on Durolane to final PA (NSA) ADD ST on Impoyz as follows: trial of a topical corticosteroid in the previous 120 days. CHANGE AGE RESTRICTION on Tuzistra XR as follows: greater than 18 years of MAINTAIN QL and ST on Tuzistra XR CHANGE AGE RESTRICTION on Codeine/Phenylephrine/ Promethazine as follows: greater than 18 years of CHANGE AGE RESTRICTION on Promethazine/Codeine as follows: greater than 18 years of FlowTuss, Obredon hydrocodone, guaifenesin 3 S=3 ST, QL Hycofenix hydrocodone, pseudoephedrine, guaifenesin 3 S=3 ST, QL A=AGE S=ST, QL A=AGE S=ST, QL ADD AGE RESTRICTION on FlowTuss, Obredon as follows: greater than 18 years of MAINTAIN ST and QL on FlowTuss, Obredon. ADD AGE RESTRICTION on Hycofenix as follows: greater than 18 years of MAINTAIN ST and QL on Hycofenix.
5 Drug Vituz hydrocodone, chlorpheniramine 3 S=3 none A=AGE ADD AGE RESTRICTION on Vituz as follows: greater than 18 years of age required. Tussionex hydrocodone, chlorpheniramine ER 12H suspension 1 S=1 none A=AGE ADD AGE RESTRICTION on Tussionex as follows: greater than 18 years of Tussicaps hydrocodone, chlorpheniramine ER CAP 3 S=3 none A=AGE ADD AGE RESTRICTION on Tussicaps as follows: greater than 18 years of Zutripro hydrocodone, chlorpheniramine, pseudophedrine 1 S=1 none A=AGE ADD AGE RESTRICTION on Zutripro as follows: greater than 18 years of Tussigon (tablet), Hydromet (syrup) 1Q18 Clean up hydrocodone/homatropine 1 S=1 none A=AGE ADD AGE RESTRICTION on Tussigon, Hydromet as follows: greater than 18 years of Cialis tadalafil (2.5, 5 mg) 3 S=3 PA, QL Cialis tadalafil (10, 20 mg) 3 S=3 PA, QL D=PA A=ST MAINTAIN QL on Cialis 2.5, 5 mg CHANGE PA guideline on Cialis 2.5, 5 mg MAINTAIN QL on Cialis 10, 20 mg DELETE PA on Cialis 10, 20 mg ADD ST on Cialis 10, 20 mg as follows: Trial of sildenafil (Viagra) in the previous 120 days. Xigduo XR dapagliflozin/metformin 3 S=3 ST, QL S=ST C=QL CHANGE QL on Xigduo XR as follows: 2.5/1000mg, 5/1000mg: 2 tablets per day; 5/500mg, 10/500 mg, 10/1000 mg: 1 tablet per day Gamunex C IVIG (40G, GPID=37322) NC^ S=NC^ none A=PA ADD PA guideline on Gamunex C (40 Gram) Vemlidy tenofovir alafenamide 4 S=4 QL 1Q18 Exclusions A=ST MAINTAIN QL on Vemlidy ADD ST on Vemlidy as follows: Trial of tenofovir 300 mg (Viread) in the previous 120 days Fenortho, Profeno, Nalfon fenoprofen 200, 400, 600 mg 2 C=3 None None CHANGE Fenortho, Profeno, Nalfon to Non Preferred Brands (Tier 3) doxycyline doxycline DR 200 mg 1 S=1 ST,QL 1Q18 IR initiatives C=QL S=ST CHANGE QL on doxycycline DR 200 as follows: 1 tablet per day. MAINTAIN ST on doxycycline DR 200mg Uptravi selexipag 4 S=4 PA CHANGE PA guideline on Uptravi. Austedo deutetrabenazine 4 S=4 PA CHANGE PA guideline on Austedo. Ingrezza valbenazine 4 S=4 PA CHANGE PA guideline on Ingrezza. Negative Changes from 4Q17 (Approved at P&T 4Q17) MISC Non Oral (IV, SC) 4Q17 Carryover Benlysta IV belimumab 4 S=4 none A=PA^ ADD PA (NSA) guideline on Benlysta IV ADHD 4Q17 Carryover Cotempla XR ODT methylphenidate ER 3 S=3 ST A=QL C=ST CHANGE ST on Cotempla XR ODT as follows: Trial of methylphenidate IR, long acting formulation of methylphenidate (ER, LA, CD), or generic/multisource mixed amphetamine salts (Adderall IR/XR) in the previous 120 days. MISC Agents 4Q17 Carryover Duzallo allopurinol/ lesinurad 3 S=3 none A=ST, QL ADD QL on Cotempla XR ODT as follows: 8.6 mg, 17.3 mg: 1 tablet per day; 25.9 mg: 2 tablets per day ADD ST on Duzallo as follows: Trial of allopurinol or Uloric (feuxostat) in the previous 120 days. ADD QL on Duzallo as follows: 1 tablet per day. Zurampic lesinurad 2 C=3 ST, QL S=ST, QL CHANGE Zurampic to Non Preferred Brands (Tier 3) Carospir spironolactone oral suspension 3 S=3 none A=ST, QL ADD ST on Carospir as follows: Trial of spironolactone tablets in the previous 120 days. ADD QL on Carospir as follows: 600 ml per 30 days Glycopyrrolate Glycopyrrolate 1.5 mg 1 S=1 none A=ST, QL Chlorzoxazone Chlorzoxazone 250, 375, 750 mg 1 S=1 none A=ST, QL Taytulla ethnityl estradiol/ noethindrone/fe 3 S=3 none A=ST ADD ST on Glycopyrrolate 1.5 mg tablets as follows: Trial of glycopyrrolate 1 mg or 2 mg tablets in the previous 120 days. ADD QL on Glycopyrrolate 1.5 mg tablets as follows: 3 tablets per day. ADD ST on Chlorzoxazone 250, 375, 750 mg tablets as follows: trial of chlorozoxane 500 mg tablets in the previous 120 days. ADD QL on Chlorzoxazone 250, 375, 750 mg tablets as follows: 4 tablets per day. ADD ST to Taytulla as follows: trial of two generic contraceptives in the previous 365 days. Renagel sevelamer HCL 2 C=3 none none CHANGE Renagel to Non Preferred Brands (Tier 3)
6 Drug Zodex/Locort/ ZonaCort/Dexpack 1Q18 Additional Item dexamethasone 1.5 mg blister pack (misc pack sizes) 3 S=3 None C=ST Forteo teriparatide SC 2 S=2 QL C=QL CHANGE ST on Zodex/Locort/Zonacort/Dexpack (dexamethasone 1.5 mg tablet taper packs) as follows: trial of dexamethasone 1.5 mg tablets required. CHANGE QL on Forteo as follows: Limited 2.4mL per 28 days with a max duration of 728 days per lifetime COMMERCIAL LEGEND Formulary s Utilization Management (UM) s C = Change A = Add UM S = Sustain D = Delete UM NC^ = Not covered; Non C = Change UM Formulary if covered E = Exclude drug from formulary S = Sustain/maintain Multiple actions view cell for details
Prescription benefit updates Individual/small group
Prescription benefit updates Individual/small group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps
More informationELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)
ELEVATE Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) P&T/Formulary Committee Actions 4Q 2017 (Effective January 1, 2018) Marketplace Standard
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationJanuary 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationThese programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.
FlexRx Standard Utilization Management (PA, QL,) Updates January 1, 2018 How to use this drug list This drug list includes updates to Utilization Management (UM) programs. UM may include a prior authorization
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationPresbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES
NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the Presbyterian Commercial Large Group Plans (Non-Metal Plans) Formularies effective 2018. For the most recent list of drugs,
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationPresbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES
NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the 2017 Presbyterian Individual and Family Metal Plan/Employer Group Metal Plan Formularies effective 2018. For the most recent
More informationPA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131
More informationFormulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary
One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for
More informationDrug Name Description of Change Formulary Coverage Formulary Alternative(s)
NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the Presbyterian Centennial Care Formulary effective 2018. For the most recent list of drugs, information on asking for a prior
More informationPA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationSubject: Vedolizumab (Entyvio ) Infusion
09-J2000-18 Original Effective Date: 09/15/14 Reviewed: 09/12/18 Revised: 01/15/19 Subject: Vedolizumab (Entyvio ) Infusion THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationMEDICATION PRIOR AUTHORIZATION CRITERIA
UNITY HEALTH PLAN MEDICATION PRI AUTHIZATION CRITERIA These medication prior authorization criteria do not apply to Unity State and Local Government members or Unity BadgerCare Plus members. State and
More informationMarch 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More informationInfusible Biologics Medical Policy Prior Authorization Program Summary
Infusible Biologics Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent
More informationPrescription benefit updates Large group
Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money
More informationSubject: Guselkumab (Tremfya ) Injection
09-J2000-87 Original Effective Date: 09/15/17 Reviewed: 09/12/18 Revised: 01/01/19 Subject: Guselkumab (Tremfya ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 04/09/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: 09/05/18 ARCHIVE DATE:
ILARIS (canakinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationTherapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol
Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has
More informationPPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Biologic Immunomodulators Therapy Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Biologic Immunomodulators Therapy (Pharmacy Benefit Only) Prime Therapeutics
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationAdded, Removed or Changed. Added, Removed or Changed
One mission: you s March 8, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationClinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.194 Effective Date: 01.01.18 Last Review Date: 12.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMEDICATION PRIOR AUTHORIZATION CRITERIA
UNITY HEALTH PLAN MEDICATION PRI AUTHIZATION CRITERIA These medication prior authorization criteria do not apply to Unity State and Local Government members or Unity BadgerCare Plus members. State and
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationClinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.194 Effective Date: 01.01.18 Last Review Date: 05.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882
More informationClinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.194 Effective Date: 01.01.18 Last Review Date: 05.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Biologic Immunomodulators Therapy Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Biologic Immunomodulators Therapy (Pharmacy Benefit Only) Prime Therapeutics
More informationCARE N CARE HEALTH PLAN
PPI DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.195 Effective Date: 11.16.16 Last Review Date: 05.18 Line of Business: Medicaid Health Net Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic
More informationRemicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade
More informationCorporate Medical Policy
Corporate Medical Policy Infliximab, Infliximab-dyyb, Infliximab-abda File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab 5/2002 2/2018 2/2019 7/2018 Description of Procedure
More informationClinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.194 Effective Date: 01.01.18 Last Review Date: 02.19 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 01/21/2015 Effective date: 02/21/2015 Therapeutic Classes reviewed: Allergen-Specific Immunotherapy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationBRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX
BRINTELLIX BRINTELLIX Claim will pay automatically for brintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, brintellix
More informationHealth Partners Medicare Special Formulary Updates
March 2018 Effective Date Brand Name Generic Name Type of Change 90 / 30 DAYS tenofovir disoproxil fumarate tenofovir disoproxil fumarate clobetasol propionate tenofovir disoproxil fumarate Previous Value
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 13 Last Review Date: September 20, 2018 Humira Description Humira (adalimumab),
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective July 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationStep Therapy Criteria
ADCIRCA ADCIRCA Coverage will be provided if the member has filled a prescription for sildenafil (at least a 30 day supply within the past 365 ) ELIDEL 76-F ELIDEL Coverage will be provided if the member
More informationSubject: Ixekizumab (Taltz ) Injection
09-J2000-62 Original Effective Date: 06/15/16 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Ixekizumab (Taltz ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationcustom fused glass tile Important Copy: custom glass tile and fused glass tile Custom Glass Tile
custom fused glass tile Custom Glass Tile Important Copy: custom glass tile and fused glass tile The parasite escapes from the liver undetected by wrapping itself in the cell membrane of the infected host
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 10 Last Review Date: June 22, 2018 Enbrel Description Enbrel (etanercept),
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective July 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationPharmacy and Therapeutics Update
Pharmacy and Therapeutics Update Summer 2017 Highlights of recent drug policy revisions, as well as any new drug policies approved by Prevea360 Health Plan s Medical Policy Committee, are shown below.
More information2018 Formulary Update
MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level 1 agent (LANTUS, LEVEMIR,
More informationSubject: Apremilast (Otezla ) Tablet
09-J2000-19 Original Effective Date: 09/15/14 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Apremilast (Otezla ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 14 Last Review Date: June 22, 2018 Humira Description Humira (adalimumab),
More informationHEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria
GLP1-INSULIN XULTOPHY SOLUTION PEN- INJECTOR 100-3.6 UNIT-MG/ML HEALTHTEAM ADVANTAGE Claim will pay automatically for Xultophy if enrollee has a paid claim for at least a one day supply for step level
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective January 1, 2019 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationRegulatory Status FDA-approved indication: Humira and its biosimilars are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-5)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 13 Last Review Date: November 30, 2018 Humira Description Humira (adalimumab),
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationNovember 2018 P & T Updates
November 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AIMOVIG 3 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY 3 2 4.5 ml
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationSubject: Ustekinumab (Stelara ) Injection and Infusion
09-J1000-16 Original Effective Date: 02/15/10 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Ustekinumab (Stelara ) Injection and Infusion THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationMEDICATION PRIOR AUTHORIZATION CRITERIA
MEDICATION PRIOR AUTHORIZATION CRITERIA These medication prior authorization criteria do not apply to State and Local Government members or BadgerCare Plus members. State and Local Government members should
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective Jan. 1, 2019 Traditional Three-Tier PDL Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount
More informationJanuary 2018 P & T Updates
January 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional BEVYXXA 3 No 2 BOSULIF 3 2 * Indicates prior authorization (PA) or step (ST) Depending on your specific benefits and in
More information